CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the CE mark approval of its next-generation LED-based illumination device, or the INT200, for the INTERCEPT Blood ...
Cerus Corporation (Nasdaq: CERS) announced today that it will host an industry workshop on the benefits of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, commonly referred to as INTERCEPT ...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today two in-country regulatory approvals for INT200, one by the French National Agency for Medicines and Health Product ...
Presentations and abstracts showcase the broad applicability and expected benefits of the INTERCEPT Blood System for platelets, plasma, IFC, and red blood cells CONCORD, Calif.--(BUSINESS WIRE)-- ...
The Company is reiterating its full-year 2025 annual product revenue guidance range of $194 million to $200 million, which includes $12 million to $15 million for INTERCEPT Fibrinogen Complex (IFC).
Cerus’ Notified Body, TÜV-SÜD, has completed the review of the clinical module for the CE Mark submission for INTERCEPT Red Blood Cells (RBCs) CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation ...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced a selection of abstracts to be presented at the 2024 Association for the Advancement of Blood & Biotherapies (AABB) ...
Regulatory Approval Allows Company to Initiate Commercialization of the Illumination Device throughout the European Union CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (CERS) announced today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback